Evidence map›Paper›PMID 37187723›Full record

ArticleEuropean urology open science2023

Single-nucleus and Spatially Resolved Intratumor Subtype Heterogeneity in Bladder Cancer.

Sia V Lindskrog, Sofie S Schmøkel, Iver Nordentoft, Philippe Lamy, Michael Knudsen, Frederik Prip, Trine Strandgaard, Jørgen Bjerggaard Jensen, Lars Dyrskjøt

Open access · goldAbstract read
In one paragraph

Article in European urology open science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. International journal of surgery (London, England) · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Bladder cancer.Nature reviews. Disease primers · 2023
    Review
  15. What is a Bladder Cancer Molecular Subtype? - Counterpoint.Bladder cancer (Amsterdam, Netherlands) · 2023
    Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sia V LindskrogDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Sofie S SchmøkelDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Iver NordentoftDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Philippe LamyDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Michael KnudsenDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Frederik PripDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Trine StrandgaardDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Jørgen Bjerggaard JensenDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Lars DyrskjøtDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Aarhus University Hospital · DKAarhus University · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Current bulk transcriptomic classification systems for bladder cancer do not consider the level of intratumor subtype heterogeneity. Objective: To investigate the extent and possible clinical impact of intratumor subtype heterogeneity across early and more advanced stages of bladder cancer. Design setting and participants: We performed single-nucleus RNA sequencing (RNA-seq) of 48 bladder tumors and additional spatial transcriptomics for four of these tumors. Total bulk RNA-seq and spatial proteomics data were available from the same tumors for comparison, along with detailed clinical follow-up of the patients. Outcome measurements and statistical analysis: The primary outcome was progression-free survival for non-muscle-invasive bladder cancer. Cox regression analysis, log-rank tests, Wilcoxon rank-sum tests, Spearman correlation, and Pearson correlation were used for statistical analysis. Results and limitations: We found that the tumors exhibited varying levels of intratumor subtype heterogeneity and that the level of subtype heterogeneity can be estimated from both single-nucleus and bulk RNA-seq data, with high concordance between the two. We found that a higher class 2a weight estimated from bulk RNA-seq data is associated with worse outcome for patients with molecular high-risk class 2a tumors. The sparsity of the data generated using the DroNc-seq sequencing protocol is a limitation. Conclusions: Our results indicate that discrete subtype assignments from bulk RNA-seq data may lack biological granularity and that continuous class scores may improve clinical risk stratification of patients with bladder cancer. Patient summary: We found that several molecular subtypes can exist within a single bladder tumor and that continuous subtype scores can be used to identify a subgroup of patients with poor outcomes. Use of these subtype scores may improve risk stratification for patients with bladder cancer, which can help in making decisions on treatment.

Indexed as

Intratumor heterogeneityMuscle-invasive bladder cancerNon–muscle-invasive bladder cancerRNA sequencingSingle-nucleus RNA sequencingSpatial transcriptomicsSubtyping

Identifiers

PMID37187723
PMCPMC10175738
OpenAlexW4362702442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.